Filing Impact
Filing Sentiment
Form Type
144
Monopar Therapeutics Inc
Aug 12, 2025
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
Jun 11, 2025
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
Jun 3, 2025
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
191.65M
4.00M
34.56%
47.59%
2.23%
Biotechnology
Pharmaceutical Preparations
United States
WILMETTE